1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F.: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase N° 11. Lyon, France: international Agency for Research on Cancer; 2013. [http://globocan.iarc.fr accessed on 17/04/2014].
2. Koutsky L. Epidemiology of Genital Human Papillomavirus Infection. Am J Med. 1997;102(5):3–8. doi: 10.1016/S0002-9343(97)00177-0.[PubMed][Cross Ref]
3. Monsonégo J. Prévention du cancer du col utérin: enjeux et perspectives de la vaccination antipapillomavirus. Gynecol Obstet Fertil. 2006;34(3):189–201. doi: 10.1016/j.gyobfe.2006.01.036.[PubMed][Cross Ref]
4. Louie SdS SK, Mayaud P. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop Med Int Health. 2009;14(10):1287–1302. doi: 10.1111/j.1365-3156.2009.02372.x.[PubMed][Cross Ref]
5. Haesebaert J, Luntringer-Magnin D, Kalecinski J, Barone G, Jacquard AC, Régnier V, Leocmach Y, Vanhems P, et al. French women’s knowledge of and attitudes towards cervical cancer prevention and the acceptability of HPV vaccination among those with 14–18 year old daughters: a quantitative-qualitative study. BMC Public Health. 2012;12:1034. doi: 10.1186/1471-2458-12-1034.[PMC free article][PubMed][Cross Ref]
6. Giles SG M. A study of women’s knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines. Aust N Z J Obstet Gynaecol. 2006;46:311–315. doi: 10.1111/j.1479-828X.2006.00598.x.[PubMed][Cross Ref]
7. Tebeu PM, Major AL, Rapiti E, Petignat P, Bouchardy C, Sando Z, de Bernis L, Ali L, Mhawech-Fauceglia P. The attitude and knowledge of cervical cancer by Cameroonian women; a clinical survey conducted in Maroua, the capital of Far North Province of Cameroon. Int J Gynecol Cancer. 2008;18(4):761–765. doi: 10.1111/j.1525-1438.2007.01066.x.[PubMed][Cross Ref]
8. Getahun F, Mazengia F, Abuhay M, Birhanu Z. Comprehensive knowledge about cervical cancer is low among women in Northwest Ethiopia. BMC Cancer. 2013;13:2. doi: 10.1186/1471-2407-13-2.[PMC free article][PubMed][Cross Ref]
9. Francis SA, Nelson J, Liverpool J, Soogun S, Mofammere N, Thorpe RJ., Jr Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa. Vaccine. 2010;28(50):8026–8032. doi: 10.1016/j.vaccine.2010.08.090.[PubMed][Cross Ref]
10. Chumnan Kietpeerakool YP, Kriangsak J, Usanee S, Jatupol S. Knowledge, awareness, and attitudes of female sex workers toward HPV infection, cervical cancer, and cervical smears in Thailand. Int J Gynecol Obstet. 2009;107:216–219. doi: 10.1016/j.ijgo.2009.07.023.[PubMed][Cross Ref]
11. Meye JFMB, Belembaogo E, Engongah-Beka T, Minko-Mi Etoua D. Place du dépistage du cancer du col utérin au Gabon, étude sur 19 ans: 1977–1995. Ann Pathol. 2001;3:233.[PubMed]
12. Moreira ED, Jr, Oliveira BG, Ferraz FM, Costa S, Costa Filho JO, Karic G. Knowledge and attitudes about human papillomavirus, Pap smears, and cervical cancer among young women in Brazil: implications for health education and prevention. Int J Gynecol Cancer. 2006;16(2):599–603. doi: 10.1111/j.1525-1438.2006.00377.x.[PubMed][Cross Ref]
13. Adanu RMK. Cervical Cancer Knowledge and Screening in Accra, Ghana. J Wom Health Gender-Based Med. 2002;11:6. doi: 10.1089/152460902760277822.[PubMed][Cross Ref]
14. Saad Ahmed KS, Suleiman I, Rukaiya A. Knowledge, attitude and practice of cervical cancer screening among market women in Zaria, Nigeria. Niger Med J. 2013;54(5):316. doi: 10.4103/0300-1652.122337.[PMC free article][PubMed][Cross Ref]
15. Ogunbode O, Ayinde OA. Awareness of cervical cancer and screening in a Nigerian female market population. Ann Afr Med Soc. 2005;4(4):160–3.
16. McFarland DM. Cervical cancer and Pap smear screening in Botswana: knowledge and perceptions. Int Nurs Rev. 2003;50(3):167–175. doi: 10.1046/j.1466-7657.2003.00195.x.[PubMed][Cross Ref]
17. Moore EE, Wark JD, Hopper JL, Erbas B, Garland SM. The roles of genetic and environmental factors on risk of cervical cancer: a review of classical twin studies. Twin Res Hum Genet. 2012;15(1):79–86. doi: 10.1375/twin.15.1.79.[PubMed][Cross Ref]
18. Were ENZ, Buziba N. Perceptions of risk and barriers to cervical cancer screening at Moi Teaching and Referral Hospital (MTRH), Eldoret, Kenya. Afr Health Sci. 2011;11(1):58–64.[PMC free article][PubMed]
19. Louie KS, De Sanjose S, Diaz M, Castellsague X, Herrero R, Meijer CJ, et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. Br J Cancer. 2009;100(7):1191–1197. doi: 10.1038/sj.bjc.6604974.[PMC free article][PubMed][Cross Ref]
20. Oh HY, Kim MK, Seo S, Lee DO, Chung YK, Lim MC, Kim J, Lee CW, Park S. Alcohol consumption and persistent infection of high-risk human papillomavirus. Epidemiol Infect. 2015;143(7):1442–50. doi: 10.1017/S0950268814002258.[PubMed][Cross Ref]
21. Austin LT, Ahmad F, McNally MJ, Stewart DE. Breast and cervical cancer screening in Hispanic women: a literature review using the health belief model. Womens Health Issues. 2002;12(3):122–128. doi: 10.1016/S1049-3867(02)00132-9.[PubMed][Cross Ref]
22. Kwok C, White K, Roydhouse JK. Chinese-Australian women’s knowledge, facilitators and barriers related to cervical cancer screening: a qualitative study. J Immigr Minor Health. 2011;13(6):1076–1083. doi: 10.1007/s10903-011-9491-4.[PubMed][Cross Ref]
23. Obi SN, Ozumba BC, Nwokocha AR, Waboso PA. Participation in highly subsidized cervical cancer screening by women in Enugu, South-east Nigeria. J Obstet Gynaecol. 2007;27(3):305–307. doi: 10.1080/01443610701227976.[PubMed][Cross Ref]
24. Vanslyke JG, Baum J, Plaza V, Otero M, Wheeler C, Helitzer DL. HPV and cervical cancer testing and prevention: knowledge, beliefs, and attitudes among Hispanic women. Qual Health Res. 2008;18(5):584–596. doi: 10.1177/1049732308315734.[PubMed][Cross Ref]
25. Al-Meer FM, Aseel MT, Al-Khalaf J, Al-Kuwari MG, Ismail MF. Knowledge, attitude and practices regarding cervical cancer and screening among women visiting primary health care in Qatar. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2011;17(11):855–861.[PubMed]
26. Kesic V, Markovic M, Matejic B, Topic L. Awareness of cervical cancer screening among women in Serbia. Gynecol Oncol. 2005;99(3 Suppl 1):S222–S225. doi: 10.1016/j.ygyno.2005.07.092.[PubMed][Cross Ref]
27. Poole DN, Tracy JK, Levitz L, Rochas M, Sangare K, Yekta S, et al. A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in Mali. PLoS One. 2013;8(2):e56402. doi: 10.1371/journal.pone.0056402.[PMC free article][PubMed][Cross Ref]
28. Francis SA, Battle-Fisher M, Liverpool J, Hipple L, Mosavel M, Soogun S, et al. A qualitative analysis of South African women’s knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health. Vaccine. 2011;29(47):8760–8765. doi: 10.1016/j.vaccine.2011.07.116.[PubMed][Cross Ref]
29. Makwe CC, Anorlu RI, Odeyemi KA. Human papillomavirus (HPV) infection and vaccines: knowledge, attitude and perception among female students at the University of Lagos, Lagos, Nigeria. J Epidemiol Global Health. 2012;2(4):199–206. doi: 10.1016/j.jegh.2012.11.001.[PubMed][Cross Ref]
30. Ezenwa BN, Balogun MR, Okafor IP. Mothers’ human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Wom Health. 2013;5:371–377. doi: 10.2147/IJWH.S44483.[PMC free article][PubMed][Cross Ref]
31. Deriemaeker H, Michielsen D, Reichman G, Devroey D, Cammu H. Knowledge about human papillomavirus and the human papillomavirus vaccine in Belgian students. Central European J Urol. 2014;67(4):410–417.[PMC free article][PubMed]
32. Blake KD, Ottenbacher AJ, Finney Rutten LJ, Grady MA, Kobrin SC, Jacobson RM, Hesse BW. Predictors of Human Papillomavirus Awareness and Knowledge in 2013: Gaps and Opportunities for Targeted Communication Strategies. Am J Prev Med. 2015;48(4):402–10. doi: 10.1016/j.amepre.2014.10.024.[PMC free article][PubMed][Cross Ref]
33. Giles M, Garland S. A study of women’s knowledge regarding human papillomavirus infection, cervical cancer and human papillomavirus vaccines. Aust New Zeal J Obstet Gynaecol. 2006;46(4):311–315. doi: 10.1111/j.1479-828X.2006.00598.x.[PubMed][Cross Ref]
Pregnancy does not seem to increase the progression of abnormal cervical cell changes. The presence of abnormal cervical cell changes or HPV does not affect the outcome of the pregnancy. Close monitoring is needed so that you and your health professional can make the best treatment decisions at each stage of the pregnancy.
An abnormal Pap test may be evaluated further with colposcopy. Colposcopy is a safe test during pregnancy.
If colposcopy shows normal tissue, then a repeat Pap test or colposcopy may be done later. Having a second test depends on the type of abnormalities reported on the first Pap test.
If colposcopy confirms abnormal tissue areas, a cervical biopsy may be done to diagnose the abnormal tissue. This level of testing is also done to make sure cervical cancer, which is rare, is not present. If a cervical biopsy is needed during pregnancy, it does not usually cause problems with the pregnancy, though the risk of bleeding is greater after the first trimester. Minor cell changes should continue to be monitored during the pregnancy and after delivery. Many minor cell changes return to normal after delivery.
Moderate to severe cell changes shown on an abnormal Pap test are always evaluated by colposcopy, and possibly cervical biopsy, to diagnose the abnormal tissue and to make sure invasive cervical cancer is not present. Follow-up Pap tests and colposcopy may be done for the rest of the pregnancy to monitor the progression of the cell changes. Moderate to severe changes can be monitored closely, and treatment can wait until after delivery. In rare cases, a procedure called a cone biopsy is needed to rule out cancer.
Invasive cervical cancer must be treated as soon as possible. It is harder to manage because of the concern for the outcome of both the woman and her pregnancy. Treatment will be managed by a team of health professionals who specialize in cancer and high-risk pregnancies.